Table 1 Baseline demographic and clinical characteristics of the study population
Characteristic | All patients | Patients with VTE |
|---|---|---|
(n = 605) (%) | (n = 71) (%) | |
Median age, years | 62 | 60 |
25th–75th percentile | 55–69 | 51–69 |
< 60 | 237 (39.2) | 32 (45.1) |
≥ 60 | 368 (60.8) | 39 (54.9) |
Sex | ||
Male | 352 (58.2) | 40 (56.3) |
Female | 253 (41.8) | 31 (43.7) |
ECGO PS | ||
0–1 | 424 (70.1) | 41 (57.7) |
2–3 | 181 (29.9) | 30 (42.3) |
Tumor histology | ||
Adenocarcinoma | 471 (77.9) | 62 (87.3) |
Non-adenocarcinoma | 134 (22.1) | 9 (12.7) |
Squamous cell carcinoma | 125 (20.7) | 8 (11.3) |
Other NSCLC | 9 (1.4) | 1 (1.4) |
Tumor Stage | ||
Localized | 137 (22.6) | 16 (22.5) |
Distant metastasis | 468 (77.4) | 55 (77.5) |
EGFR gene | ||
Wild | 361 (59.7) | 49 (69.0) |
Mutated | 244 (40.3) | 22 (31.0) |
KRAS gene | ||
Wild | 543 (89.8) | 61 (85.9) |
Mutated | 62 (10.2) | 10 (14.1) |
Treatment during observation period | ||
Other treatment without TKI | 220 (36.4) | 27 (38.0) |
Other treatment with TKI | 96 (15.9) | 13 (18.3) |
TKI alone | 141 (23.3) | 11 (15.5) |
Chemotherapy alone | 148 (24.5) | 20 (28.2) |